Free Trial
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

$2.71
+0.04 (+1.50%)
(As of 12:50 PM ET)

About iBio Stock (NYSEAMERICAN:IBIO)

Key Stats

Today's Range
$2.58
$2.72
50-Day Range
N/A
52-Week Range
$1.02
$6.47
Volume
20,016 shs
Average Volume
1.22 million shs
Market Capitalization
$9.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

iBio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
5th Percentile Overall Score

IBIO MarketRank™: 

iBio scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Book Value per Share Ratio

    iBio has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.38% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iBio has recently increased by 123.53%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    iBio does not currently pay a dividend.

  • Dividend Growth

    iBio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.38% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iBio has recently increased by 123.53%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    2 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added iBio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iBio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.12% of the stock of iBio is held by insiders.

  • Percentage Held by Institutions

    Only 7.90% of the stock of iBio is held by institutions.

  • Read more about iBio's insider trading history.
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

A new way to play the AI boom (act before November 19)
There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.
IBio In Partnership With AstralBio; Shares Up In Pre-market
See More Headlines

IBIO Stock Analysis - Frequently Asked Questions

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Mesoblast (MESO), Mobileye Global (MBLY), KULR Technology Group (KULR), IonQ (IONQ), Guardforce AI (GFAI), Fastly (FSLY) and Exscientia (EXAI).

Company Calendar

Today
11/04/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:IBIO
CIK
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-65,010,000.00
Pretax Margin
-41,546.00%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$15.15 per share

Miscellaneous

Free Float
3,445,000
Market Cap
$9.29 million
Optionable
N/A
Beta
-3.77
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NYSEAMERICAN:IBIO) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners